argenx SE (ARGX) Earnings
argenx SE is expected to report next earnings on July 23, 2026 (in NaN days), with a consensus EPS estimate of $5.86. ARGX has beaten EPS estimates in 4 of its last 7 reported quarters (average surprise +367.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $6.00 | $5.90 | -1.7% | $2.4B | +67.2% |
| Oct 30, 2025 | $4.37 | $5.18 | +18.5% | $948M | -25.7% |
| May 8, 2025 | $0.98 | $2.58 | +163.3% | $1.3B | +56.2% |
| Mar 31, 2025 | — | $2.58 | — | $791M | — |
| Oct 31, 2024 | $0.10 | $1.39 | +1290.0% | $902M | +35.6% |
| Sep 30, 2024 | — | $1.39 | — | $573M | — |
| May 9, 2024 | $-0.71 | $-1.04 | -46.5% | $758M | +34.4% |
| Mar 31, 2024 | — | $-1.04 | — | $401M | — |
| Oct 31, 2023 | $-1.48 | $-1.25 | +15.5% | $468M | — |
| Sep 30, 2023 | — | $-1.25 | — | $330M | — |
| Jun 21, 2023 | — | $0.82 | — | $-258M | — |
| Oct 27, 2022 | $-3.50 | $-4.26 | -21.7% | $111M | -4.1% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Focus on building pipeline through partnerships with academic institutions and strategic investments in novel biology like Forte and Tensegrity. - MG is currently the majority of revenues and profits, with PFS driving growth. - DGF study for impasse pruvat is an exploratory phase two study with data followed out to 52 weeks for go/no-go decision on phase three. - Partnership with UNP for oral FCRN is progressing well and seen as a way to expand the market. - Combination strategy in INI, with platform studies to test different combinations for substantial efficacy benefits without safety trade-offs.